丹参注射液联合抗栓治疗急性冠脉综合征的疗效观察

Observation on the Efficacy of Danshen Injection Combined with Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome

【目的】探讨丹参注射液联合抗栓治疗急性冠脉综合征（ACS）的疗效。[方法]60例ACS患者分为治疗组和对照组，对照组采用常规强化抗栓三联方案治疗，治疗组采用丹参注射液联合常规强化抗栓三联方案治疗，治疗1周后评价疗效，检测并比较治疗前后凝血酶原时间（PT）、纤维蛋白原（Fib）、凝血酶时间（TT）、活化部分凝血酶时间（APTT）水平。【结果】治疗组总有效率为96．7％，显著高于对照组（80．0％）（P〈0．05）；治疗组治疗后PT、TT、APTT水平显著升高，Fib显著降低，与治疗前和对照组比较有显著性差异（P〈0．05）；治疗组不良事件发生率显著低于对照组（P〈0．05），且无出血事件发生。【结论】丹参注射液联合强化抗栓治疗ACS疗效满意，可改善患者体内的高凝状态，增强抗栓效果和减少出血事件的发生。

[Objective] To explore the efficacy of Danshen injection combined with antithrombotic therapy for the treatment of patients with acute coronary syndrome（ACS）. [Methods] Totally 60 ACS patients were divided into the treatment group and control group. The control group was treated with conventional antithrombotic triple regimen, while the treatment group was given Danshen injection combined with conventional antithrombotic triple regimen. Clinical efficacy was assessed after treatment for a week. Prothrombin time（PT）, fibrinogen（Fib）, thrombin time（TT） and activated partial thromboplastin time（APTT） before and after treatment were detected and compared. [Results] The total effective rate of treatment group was 96.7~./00 which was markedly higher than that of control group（80.0 ~）, and there was significant difference（ P d0.05）. After treatment, PT, TT and APTT of treatment group increased markedly, while Fib decreased markedly, and there was Significant difference between before treatment and control group （ P ~ 0. 05）. The incident rate of adverse events in treatment group was markedly lower than that in control group（ P d0.05）, and no bleeding occurred. [Conclusion] Danshen injection combined with intensified antithrombotic therapy for the treatment of ACS has satisfactory efficacy, and can improve the hypercoagulable state in the body, and increase antithrombotic effect, and reduce bleeding events.